Brokers Offer Predictions for CNTB Q1 Earnings

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Monday, March 31st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at ($0.22) EPS.

Connect Biopharma Price Performance

Shares of Connect Biopharma stock opened at $0.59 on Thursday. The business has a 50-day simple moving average of $0.86 and a 200-day simple moving average of $1.05. Connect Biopharma has a one year low of $0.55 and a one year high of $2.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Choreo LLC purchased a new stake in shares of Connect Biopharma during the 4th quarter worth $204,000. Callan Capital LLC raised its stake in Connect Biopharma by 91.3% in the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after buying an additional 38,177 shares in the last quarter. Finally, Catalina Capital Group LLC purchased a new stake in Connect Biopharma during the 4th quarter worth about $66,000. Institutional investors and hedge funds own 58.72% of the company’s stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.